ImaginAb Secures $12,500,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b40f9f70-c165-4a4e-a2b5-5a504b6c52e9&Preview=1 - Date
3/28/2012 - Company Name
ImaginAb - Mailing Address
Undisclosed Los Angeles, CA 90049 - Company Description
ImaginAb’s mission is to transform the clinical management of cancer and autoimmune diseases via targeted molecular imaging. We re-engineer therapeutic antibodies against biologically important targets into small proteins optimized for diagnostic imaging with Positron Emission Tomography (PET). We believe that in the era of targeted molecular therapy, there is a major unmet need for true companion in vivo diagnostics to help realize the promise of personalized medicine. - Website
http://www.imaginab.com - Transaction Type
Venture Equity - Transaction Amount
$12,500,000 - Transaction Round
Series A - Proceeds Purposes
It says the funds will be used to speed clinical development of its cancer and immunology imaging programs, which are focused on the staging of metastatic prostate and pancreatic cancer. - M&A Terms
- Venture Investor
Novartis Venture Fund - Venture Investor
Undisclosed
